The final, formatted version of the article will be published soon. The interaction between p53 and MDM2 represents a key therapeutic target in several cancers where MDM2 overexpression suppresses p53 ...

This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...

SA53 is a genetically targeted therapeutic designed to reactivate the tumor suppressor protein p53 commonly referred to as the “Guardian of the Genome by inhibiting the MDM2 protein, which typically ...

A class of drugs, MDM2 inhibitors, being studied as cancer therapeutics may accidentally damage the protective barriers in the brain and eyes, finds new research in mice. New research at the ...

Summary: Researchers have uncovered a surprising connection between a cancer-related signaling pathway and the blood-brain and blood-retina barriers. The study shows that the tumor-suppressing protein ...

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in ...

Scientists have recently shed some light on exactly why elephants, one of the biggest animals on the planet, paradoxically experience unusually low rates of cancer. The research found these remarkable ...

Co-first author Shiekh Tanveer Ahmad, PhD, co-senior author Hong Lin, PhD, co-author Jennifer Hadley and senior co-corresponding author Paul Northcott, PhD, St. Jude Center of Excellence in ...

Myelofibrosis causes anemia, splenomegaly, and other symptoms, creating unmet treatment needs. The POIESIS trial explores navtemadlin as an add-on to Jakafi for suboptimal responders. Navtemadlin ...

ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and ...

Introduction: Murine double minute 2 (MDM2), a key negative regulator of p53, forms a feedback loop with p53 to drive tumor progression, including colorectal cancer. Nutlin-3a, an MDM2 inhibitor, ...

Myeloproliferative disorders (MPDs) are a group of blood cancers traditionally treated using medications, blood filtration, and chemotherapy or radiation. In recent news, several studies and clinical ...